Cytokinetics Common Stock

Cytokinetics (CYTK) currently reports a common stock of $140K as of June 2026. That compares with $120K in the prior-year period — up 16.0% year over year. Use the charts on this page to explore Cytokinetics's common stock history and peer comparisons.

Cytokinetics's common stock increased from $120K to $140K — a 16.0% year-over-year increase (period ending June 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Cytokinetics reported $140K in common stock as of June 2026. That compares with $120K in the prior-year period — up 16.0% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current common stock of $140K, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for Cytokinetics, and consider following CYTK for alerts when major investors trade the stock.

Cytokinetics is classified in the Healthcare sector. On common stock, it currently shows $140K. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing CYTK with unrelated industries.